stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Revenue
Haleon PLC Sponsored ADR's revenue for fiscal 2025 was $14.5B, unchanged from fiscal 2024. Over the past ten years it has ranged from $11.2B (fiscal 2019) to $14.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Haleon PLC Sponsored ADR ranks 2nd of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $14.5B | 1.33% |
| FY2024 | $14.4B | 2.11% |
| FY2023 | $14.1B | 4.68% |
| FY2022 | $13.4B | 4.12% |
| FY2021 | $12.9B | (4.81%) |
| FY2020 | $13.6B | 21.44% |
| FY2019 | $11.2B | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2024 | $3.6B | (2.32%) |
| Mar 2024 | $3.7B | 4.51% |
| Sep 2023 | $3.5B | (51.23%) |
| Jun 2023 | $7.3B | 100.23% |
| 1 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $30.0B |
| HLN Haleon PLC Sponsored ADR | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.2B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation compare | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HLN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement